RCM
TOVX icon

Rotella Capital Management’s Theriva Biologics TOVX Stock Holding History

Rotella Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2
Closed -$58K – 660
2015
Q2 		$58K Buy
+2
New +$40.1K 0.05% 357

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rotella Capital Management's TOVX Position: Q3 2015 in Review

Rotella Capital Management sold out of Theriva Biologics (TOVX) in Q3 2015, closing a stake of 2 shares — an estimated $58K sold.

Rotella Capital Management first reported a position in TOVX in Q2 2015 and held it in 1 quarter. The position peaked at $58K in Q2 2015. 45 funds tracked by Wall St. Rank hold TOVX as of Q3 2015.

  • Rotella Capital Management reported no remaining Theriva Biologics position as of Q3 2015 after selling out during the quarter.
  • Rotella Capital Management sold 2 Theriva Biologics shares in Q3 2015, an estimated $58K.
  • Rotella Capital Management first reported a position in Theriva Biologics in Q2 2015 and held it in 1 quarter.
  • Rotella Capital Management's Theriva Biologics position peaked at $58K in Q2 2015.
  • 45 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2015.

Based on Rotella Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.